BBZA Financial Statements From 2010 to 2024
| BBZA Stock | EUR 39.20 0.70 1.82% |
Check BB Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BB Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . BBZA financial statements analysis is a perfect complement when working with BB Biotech Valuation or Volatility modules.
BBZA |
BB Biotech AG Company Shares Outstanding Analysis
BB Biotech's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current BB Biotech Shares Outstanding | 54.85 M |
Most of BB Biotech's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BB Biotech AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, BB Biotech AG has 54.85 M of shares currently outstending. This is 69.62% lower than that of the Healthcare sector and 48.67% lower than that of the Biotechnology industry. The shares outstanding for all Germany stocks is 90.41% higher than that of the company.
BB Biotech AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BB Biotech's current stock value. Our valuation model uses many indicators to compare BB Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BB Biotech competition to find correlations between indicators driving BB Biotech's intrinsic value. More Info.BB Biotech AG is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BB Biotech's earnings, one of the primary drivers of an investment's value.About BB Biotech Financial Statements
BB Biotech stakeholders use historical fundamental indicators, such as BB Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although BB Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in BB Biotech's assets and liabilities are reflected in the revenues and expenses on BB Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BB Biotech AG. Please read more on our technical analysis and fundamental analysis pages.
Currently Active Assets on Macroaxis
Other Information on Investing in BBZA Stock
BB Biotech financial ratios help investors to determine whether BBZA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBZA with respect to the benefits of owning BB Biotech security.